Menu Search
Equities

JOHNSON DRN

JNJB34:SAO

JOHNSON DRN

Actions
  • Price (BRL)57.00
  • Today's Change-0.78 / -1.35%
  • Shares traded1.39k
  • 1 Year change+5.17%
  • Beta--
Data delayed at least 15 minutes, as of Jul 22 2024 15:18 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		JNJ:NYQ since
announced		Transaction
value
Shockwave Medical IncAnnounced05 Apr 202405 Apr 2024Announced1.01%14.07bn
Ambrx Biopharma IncDeal completed08 Jan 202408 Jan 2024Deal completed-4.40%1.98bn
Data delayed at least 15 minutes, as of Jul 22 2024 15:18 BST.

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Ita� Unibanco SAas of 31 Mar 2024198.79k0.00%
Bram Bradesco Asset Management S/A DTVMas of 31 Mar 202475.01k0.00%
Banco J. Safra SAas of 31 Mar 202457.62k0.00%
Safra Asset Management Ltda.as of 31 Mar 202455.20k0.00%
Caixa DTVM SAas of 31 Mar 202436.91k0.00%
Warren Brasil Gest�o e Administra��o e Recursos Ltda.as of 31 Mar 20249.69k0.00%
BTG Pactual WM Gest�o de Recursos Ltda.as of 31 Mar 20247.15k0.00%
Western Asset Management Company DTVM Ltda.as of 31 Mar 20241.43k0.00%
BB Gest�o de Recursos DTVM SAas of 31 Mar 20240.000.00%
More ▼
Data from 31 Mar 2024 - 18 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.